Fredun [FREDUN] vs Gujarat Themis [GUJTHEM] Detailed Stock Comparison

Fredun Pharmaceuticals Ltd.

BSE
Loading...

Gujarat Themis Biosyn Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Fredun Pharmaceuticals Ltd. wins in 9 metrics, Gujarat Themis Biosyn Ltd. wins in 11 metrics, with 0 ties. Gujarat Themis Biosyn Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Fredun Pharmaceuticals Ltd. Gujarat Themis Biosyn Ltd. Better
P/E Ratio (TTM) 29.83 73.73 Fredun Pharmaceuticals Ltd.
Price-to-Book Ratio 6.26 13.36 Fredun Pharmaceuticals Ltd.
Debt-to-Equity Ratio 108.78 27.04 Gujarat Themis Biosyn Ltd.
PEG Ratio 0.31 -17.55 Fredun Pharmaceuticals Ltd.
EV/EBITDA 13.98 52.76 Fredun Pharmaceuticals Ltd.
Profit Margin (TTM) 5.53% 29.99% Gujarat Themis Biosyn Ltd.
Operating Margin (TTM) 15.26% 40.16% Gujarat Themis Biosyn Ltd.
EBITDA Margin (TTM) 15.26% 40.16% Gujarat Themis Biosyn Ltd.
Return on Equity 13.96% 19.64% Gujarat Themis Biosyn Ltd.
Return on Assets (TTM) 4.05% 16.19% Gujarat Themis Biosyn Ltd.
Free Cash Flow (TTM) $-351.69M $-251.22M Gujarat Themis Biosyn Ltd.
Dividend Yield 0.09% 0.17% Gujarat Themis Biosyn Ltd.
1-Year Return 183.86% 15.75% Fredun Pharmaceuticals Ltd.
Price-to-Sales Ratio (TTM) 1.93 22.23 Fredun Pharmaceuticals Ltd.
Enterprise Value $11.27B $36.09B Gujarat Themis Biosyn Ltd.
EV/Revenue Ratio 1.91 22.65 Fredun Pharmaceuticals Ltd.
Gross Profit Margin (TTM) 28.72% 83.29% Gujarat Themis Biosyn Ltd.
Revenue per Share (TTM) $1,273 $15 Fredun Pharmaceuticals Ltd.
Earnings per Share (Diluted) $69.90 $4.40 Fredun Pharmaceuticals Ltd.
Beta (Stock Volatility) 0.46 -0.17 Gujarat Themis Biosyn Ltd.

Fredun Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd. Stock Performance Analysis

Loading Price Chart...

FREDUN
GUJTHEM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Fredun Pharmaceuticals Ltd.0.17%0.73%-2.19%43.43%39.40%50.67%
Gujarat Themis Biosyn Ltd.-0.57%-4.89%4.00%38.98%-1.40%-12.59%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Fredun Pharmaceuticals Ltd.183.86%158.56%447.18%11,453.75%18,386.00%18,386.00%
Gujarat Themis Biosyn Ltd.15.75%76.92%76.92%76.92%76.92%76.92%

Performance & Financial Health Analysis: Fredun Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.

MetricFREDUNGUJTHEM
Market Information
Market Cap i₹11.55B₹35.41B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i11,25979,452
90 Day Avg. Volume i9,301106,446
Last Close₹2,314.65₹385.10
52 Week Range₹791.00 - ₹2,620.00₹225.05 - ₹479.00
% from 52W High-11.65%-19.60%
All-Time High₹2,620.00 (May 25, 2026)₹479.00 (Oct 27, 2025)
% from All-Time High-11.65%-19.60%
Growth Metrics
Quarterly Revenue Growth0.57%0.10%
Quarterly Earnings Growth0.97%-0.04%
Financial Health
Profit Margin (TTM) i0.06%0.30%
Operating Margin (TTM) i0.15%0.40%
Return on Equity (TTM) i0.14%0.20%
Debt to Equity (MRQ) i108.7827.04
Cash & Liquidity
Book Value per Share (MRQ)₹333.11₹24.29
Cash per Share (MRQ)₹18.49₹0.92
Operating Cash Flow (TTM) i₹-1,140,997,000₹970.68M
Levered Free Cash Flow (TTM) i₹197.39M₹487.72M
Dividends
Last 12-Month Dividend Yield i0.09%0.17%
Last 12-Month Dividend i₹0.70₹0.67

Valuation & Enterprise Metrics Analysis: Fredun Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.

MetricFREDUN (Apr 24, 2026)GUJTHEM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i29.8373.73
Forward P/E iN/AN/A
PEG Ratio i0.31-17.55
Price to Sales (TTM) i1.9322.23
Price to Book (MRQ) i6.2613.36
Market Capitalization
Market Capitalization i₹11.55B₹35.41B
Enterprise Value i₹11.27B₹36.09B
Enterprise Value Metrics
Enterprise to Revenue i1.9122.65
Enterprise to EBITDA i13.9852.76
Risk & Other Metrics
Beta i0.46-0.17
Book Value per Share (MRQ) i₹333.11₹24.29

Financial Statements Comparison: Fredun Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricFREDUN (2025)GUJTHEM (2025)
Revenue/Sales i4.52B1.51B
Cost of Goods Sold i3.45B318.78M
COGS % of Revenue i76.5%21.1%
Gross Profit i1.06B1.19B
Gross Margin i23.5%78.9%
Research & Development i49.76M34.37M
Operating Income (EBIT) i475.31M642.49M
Operating Margin i10.5%42.6%
EBITDA i530.69M713.04M
EBITDA Margin i11.7%47.3%
Pre-Tax Income i274.94M655.38M
Pre-Tax Income % of Revenue i6.1%43.5%
Income Tax i77.54M167.66M
Income Tax % of Revenue i1.7%11.1%
Net Income (Profit) i197.39M487.72M
Profit Margin i4.4%32.3%

Balance Sheet & Liquidity Metrics

MetricFREDUN (2025)GUJTHEM (2025)
Cash & Equivalents i6.37M116.94M
Total Current Assets i4.28B519.73M
Total Current Assets % of Revenue i94.7%34.5%
Total Current Liabilities i3.28B205.60M
Total Current Liabilities % of Revenue i72.6%13.6%
Long-Term Debt i96.13M296.36M
Long-Term Debt % of Revenue i2.1%19.7%
Total Shareholders Equity i1.41B2.48B
Retained Earnings i628.39M2.37B
Retained Earnings % of Revenue i13.9%157.4%
Property, Plant & Equipment i95.24M411.30M

Cash Flow Statement Comparison

MetricFREDUN (2025)GUJTHEM (2025)
Operating Cash Flow i-1.14B970.68M
Operating Cash Flow % of Revenue i-25.3%64.4%
Capital Expenditures i-59.94M-1.16B
Free Cash Flow i-351.69M-251.22M
FCF Margin i-7.8%-16.7%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricFREDUNGUJTHEM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i5.47M108.97M
Float Shares i534,24129.52M
% Held by Insiders i53.36%71.98%
% Held by Institutions i0.00%1.18%
% Held by Public i46.64%26.84%

Dividend Analysis & Yield Comparison: Fredun Pharmaceuticals Ltd. vs Gujarat Themis Biosyn Ltd.

MetricFREDUNGUJTHEM
Last 12-Month Dividend i₹0.70₹0.67
Last 12-Month Dividend Yield i0.09%0.17%
3-Year Avg Annual Dividend i₹0.70₹0.22
3-Year Avg Dividend Yield i0.08%0.17%
3-Year Total Dividends i₹2.10₹0.67
Ex-Dividend DateSep 23, 2024Sep 04, 2025